VivoSeq
Other

Endotoxemia

0

Pipeline Programs↗

0

Active Trials↗

2

Companies Involved↗

Endotoxemia is an early-stage landscape with 0 programs across 2 companies. The most active players are TME Pharma AG, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

T

TME Pharma AG

0 programs

PreclinicalA

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

16

clinical trials

Completed15 · 94%
Unknown status1 · 6%

Clinical Trials

Trial Activity

16 trials

Fenofibrate and Omega-3 Fatty Acid Modulation of Endotoxemia
Completed·UUniversity of Pennsylvania·N/A·NCT01048502·100 enrolled
Pharmacokinetics/Pharmacodynamics of NOX-H94 in the Human Endotoxemia Model
Completed·TTME Pharma AG·Phase 1·NCT01522794·24 enrolled
PK/PD of EA-230 During Endotoxemia
Completed·RRadboud University Medical Center·Phase 1·NCT02629874·60 enrolled
Blockade of Vascular Potassium Channels During Human Endotoxemia
Completed·RRadboud University Medical Center·Phase 1·NCT00185003·36 enrolled
Effect of Gemigliptin on Metabolic Endotoxemia and Lipemia
Completed·SSeoul National University Hospital·N/A·NCT02186080·10 enrolled
The Genetics of Evoked Responses to Niacin and Endotoxemia: The GENE Study
Completed·UUniversity of Pennsylvania·N/A·NCT00953667·400 enrolled
Effects of Iron Loading and Iron Chelation Therapy on Innate Immunity During Human Endotoxemia
Completed·RRadboud University Medical Center·N/A·NCT01349699·30 enrolled
The Effects of Human Endotoxemia on Functional Capacity of Hematopoietic Stem and Progenitor Cells
Completed·RRadboud University Medical Center·N/A·NCT05570643·12 enrolled
Ticagrelor in Human Endotoxemia Response to Human Endotoxemia
Completed·RRadboud University Medical Center·N/A·NCT02612480·40 enrolled
Vorapaxar in the Human Endotoxemia Model
Completed·MMedical University of Vienna·Phase 4·NCT02875028·16 enrolled
The Effects of Epinephrine in Endotoxemia in Normal Volunteers
Completed·RRutgers, The State University of New Jersey·Phase 1·NCT00753402·37 enrolled
Safety and Feasibility of an Endotoxemia Model
Completed·PPenn State University·Phase 1·NCT01329965·6 enrolled
Effect of Selective iNOS Inhibition During Human Endotoxemia
Completed·RRadboud University Medical Center·Phase 1·NCT00184990·7 enrolled
Sevelamer for Reducing Endotoxemia and Immune Activation
Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 2·NCT01543958·40 enrolled
Defibrotide in the Human Endotoxemia Model --- an Exploratory Trial Investigating the Effects and the Mechanisms of Defibrotide
Completed·—·Phase 4·NCT02876601·20 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)